Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 59 entries
Sorted by: Best Match Show Resources per page
Trends in the performance of Syrian physicians in the National Resident Matching Program.

Avicenna journal of medicine

Alsayid M, Jandali IS, Alahdab F.
PMID: 31903391
Avicenna J Med. 2019 Oct 03;9(4):154-159. doi: 10.4103/ajm.AJM_140_19. eCollection 2019.

PURPOSE: International medical graduates (IMGs) make up one-fourth of the physician workforce in the US and a significant proportion of them come from Syria. The aim of this study was to assess the performance of Syrian physicians seeking residency...

Cite
Alsayid M, Jandali IS, Alahdab F. Trends in the performance of Syrian physicians in the National Resident Matching Program. Avicenna J Med. 2019;9(4):154-159doi: 10.4103/ajm.AJM_140_19.
Alsayid, M., Jandali, I. S., & Alahdab, F. (2019). Trends in the performance of Syrian physicians in the National Resident Matching Program. Avicenna journal of medicine, 9(4), 154-159. https://doi.org/10.4103/ajm.AJM_140_19
Alsayid, Muhammad, et al. "Trends in the performance of Syrian physicians in the National Resident Matching Program." Avicenna journal of medicine vol. 9,4 (2019): 154-159. doi: https://doi.org/10.4103/ajm.AJM_140_19
Alsayid M, Jandali IS, Alahdab F. Trends in the performance of Syrian physicians in the National Resident Matching Program. Avicenna J Med. 2019 Oct 03;9(4):154-159. doi: 10.4103/ajm.AJM_140_19. eCollection 2019. PMID: 31903391; PMCID: PMC6796307.
Copy Download .nbib Format: NLM
Antibiotic Resistance in Syria: A Local Problem Turns Into a Global Threat.

Frontiers in public health

Jakovljevic M, Al Ahdab S, Jurisevic M, Mouselli S.
PMID: 30116726
Front Public Health. 2018 Aug 02;6:212. doi: 10.3389/fpubh.2018.00212. eCollection 2018.

Pharmaceutical sector of Syrian Arab Republic before the war was characterized by bold and successful development since the late 1980s. With the beginning of war in the country back in March 2011, momentum has changed significantly. Traumatism, communicable diseases...

Cite
Jakovljevic M, Al Ahdab S, Jurisevic M, et al. Antibiotic Resistance in Syria: A Local Problem Turns Into a Global Threat. Front Public Health. 2018;6:212doi: 10.3389/fpubh.2018.00212.
Jakovljevic, M., Al Ahdab, S., Jurisevic, M., & Mouselli, S. (2018). Antibiotic Resistance in Syria: A Local Problem Turns Into a Global Threat. Frontiers in public health, 6212. https://doi.org/10.3389/fpubh.2018.00212
Jakovljevic, Mihajlo, et al. "Antibiotic Resistance in Syria: A Local Problem Turns Into a Global Threat." Frontiers in public health vol. 6 (2018): 212. doi: https://doi.org/10.3389/fpubh.2018.00212
Jakovljevic M, Al Ahdab S, Jurisevic M, Mouselli S. Antibiotic Resistance in Syria: A Local Problem Turns Into a Global Threat. Front Public Health. 2018 Aug 02;6:212. doi: 10.3389/fpubh.2018.00212. eCollection 2018. PMID: 30116726; PMCID: PMC6084506.
Copy Download .nbib Format: NLM
COVERING THE COVER.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology

Alahdab YÖ.
PMID: 29755008
Turk J Gastroenterol. 2018 May;29(3):254-255. doi: 10.5152/tjg.2018.180418.

No abstract available.

Cite
Alahdab YÖ. COVERING THE COVER. Turk J Gastroenterol. 2018;29(3):254-255doi: 10.5152/tjg.2018.180418.
Alahdab, Y. �. �. (2018). COVERING THE COVER. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 29(3), 254-255. https://doi.org/10.5152/tjg.2018.180418
Alahdab, Yeşim Özen. "COVERING THE COVER." The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology vol. 29,3 (2018): 254-255. doi: https://doi.org/10.5152/tjg.2018.180418
Alahdab YÖ. COVERING THE COVER. Turk J Gastroenterol. 2018 May;29(3):254-255. doi: 10.5152/tjg.2018.180418. PMID: 29755008; PMCID: PMC6284659.
Copy Download .nbib Format: NLM
Syrians' alternative to a health care system: "field hospitals".

Avicenna journal of medicine

Alahdab F, Omar MH, Alsakka S, Al-Moujahed A, Atassi B.
PMID: 24982824
Avicenna J Med. 2014 Jul;4(3):51-2. doi: 10.4103/2231-0770.133329.

No abstract available.

Cite
Alahdab F, Omar MH, Alsakka S, et al. Syrians' alternative to a health care system: "field hospitals". Avicenna J Med. 2014;4(3):51-2doi: 10.4103/2231-0770.133329.
Alahdab, F., Omar, M. H., Alsakka, S., Al-Moujahed, A., & Atassi, B. (2014). Syrians' alternative to a health care system: "field hospitals". Avicenna journal of medicine, 4(3), 51-2. https://doi.org/10.4103/2231-0770.133329
Alahdab, Fares, et al. "Syrians' alternative to a health care system: "field hospitals"." Avicenna journal of medicine vol. 4,3 (2014): 51-2. doi: https://doi.org/10.4103/2231-0770.133329
Alahdab F, Omar MH, Alsakka S, Al-Moujahed A, Atassi B. Syrians' alternative to a health care system: "field hospitals". Avicenna J Med. 2014 Jul;4(3):51-2. doi: 10.4103/2231-0770.133329. PMID: 24982824; PMCID: PMC4065459.
Copy Download .nbib Format: NLM
Polio in Syria: Problem still not solved.

Avicenna journal of medicine

Al-Moujahed A, Alahdab F, Abolaban H, Beletsky L.
PMID: 28469988
Avicenna J Med. 2017 Apr-Jun;7(2):64-66. doi: 10.4103/ajm.AJM_173_16.

The reappearance of polio in Syria in mid-2013, 18 years after it was eliminated from the country, manifests the public health catastrophe brought on by the civil war. Among the lessons learned, this outbreak emphasizes the importance of increasing...

Cite
Al-Moujahed A, Alahdab F, Abolaban H, et al. Polio in Syria: Problem still not solved. Avicenna J Med. 2017;7(2):64-66doi: 10.4103/ajm.AJM_173_16.
Al-Moujahed, A., Alahdab, F., Abolaban, H., & Beletsky, L. (2017). Polio in Syria: Problem still not solved. Avicenna journal of medicine, 7(2), 64-66. https://doi.org/10.4103/ajm.AJM_173_16
Al-Moujahed, Ahmad, et al. "Polio in Syria: Problem still not solved." Avicenna journal of medicine vol. 7,2 (2017): 64-66. doi: https://doi.org/10.4103/ajm.AJM_173_16
Al-Moujahed A, Alahdab F, Abolaban H, Beletsky L. Polio in Syria: Problem still not solved. Avicenna J Med. 2017 Apr-Jun;7(2):64-66. doi: 10.4103/ajm.AJM_173_16. PMID: 28469988; PMCID: PMC5398005.
Copy Download .nbib Format: NLM
Inhaled nitric oxide for treating pain crises in people with sickle cell disease.

The Cochrane database of systematic reviews

Aboursheid T, Albaroudi O, Alahdab F, Hanuscin DL, Lee MH.
PMID: 31603241
Cochrane Database Syst Rev. 2019 Oct 11;10:CD011808. doi: 10.1002/14651858.CD011808.pub2. Epub 2019 Oct 11.

BACKGROUND: In people with sickle cell disease, sickled red blood cells cause the occlusion of small blood vessels which presents as episodes of severe pain known as pain crises or vaso-occlusive crises. The pain can occur in the bones,...

Cite
Aboursheid T, Albaroudi O, Alahdab F, et al. Inhaled nitric oxide for treating pain crises in people with sickle cell disease. Cochrane Database Syst Rev. 2019;10:CD011808doi: 10.1002/14651858.CD011808.pub2.
Aboursheid, T., Albaroudi, O., Alahdab, F., Hanuscin, D. L., & Lee, M. H. (2019). Inhaled nitric oxide for treating pain crises in people with sickle cell disease. The Cochrane database of systematic reviews, 10CD011808. https://doi.org/10.1002/14651858.CD011808.pub2
Aboursheid, Tarek, et al. "Inhaled nitric oxide for treating pain crises in people with sickle cell disease." The Cochrane database of systematic reviews vol. 10 (2019): CD011808. doi: https://doi.org/10.1002/14651858.CD011808.pub2
Aboursheid T, Albaroudi O, Alahdab F, Hanuscin DL, Lee MH. Inhaled nitric oxide for treating pain crises in people with sickle cell disease. Cochrane Database Syst Rev. 2019 Oct 11;10:CD011808. doi: 10.1002/14651858.CD011808.pub2. Epub 2019 Oct 11. PMID: 31603241; PMCID: PMC6788324.
Copy Download .nbib Format: NLM
Aspirin dosage for the prevention of graft occlusion in people undergoing coronary surgery: A systematic review and meta-analysis.

Avicenna journal of medicine

Alahdab F, Zuhri Yafi R, Chaar A, Alrstom A, Alzuabi M, Alhalabi O, Hasan S, Mallak M, Jazayerli ML, Haydour Q, Alkhouli M, Alfarkh W, Murad MH.
PMID: 33437691
Avicenna J Med. 2020 Oct 13;10(4):198-207. doi: 10.4103/ajm.ajm_17_20. eCollection 2020.

BACKGROUND: Aspirin is almost always used after coronary artery bypass graft (CABG) surgery; however, it is unclear what optimal dose should be prescribed. In this systematic review, we evaluated the effects of high versus low-dose aspirin in patients after...

Cite
Alahdab F, Zuhri Yafi R, Chaar A, et al. Aspirin dosage for the prevention of graft occlusion in people undergoing coronary surgery: A systematic review and meta-analysis. Avicenna J Med. 2020;10(4):198-207doi: 10.4103/ajm.ajm_17_20.
Alahdab, F., Zuhri Yafi, R., Chaar, A., Alrstom, A., Alzuabi, M., Alhalabi, O., Hasan, S., Mallak, M., Jazayerli, M. L., Haydour, Q., Alkhouli, M., Alfarkh, W., & Murad, M. H. (2020). Aspirin dosage for the prevention of graft occlusion in people undergoing coronary surgery: A systematic review and meta-analysis. Avicenna journal of medicine, 10(4), 198-207. https://doi.org/10.4103/ajm.ajm_17_20
Alahdab, Fares, et al. "Aspirin dosage for the prevention of graft occlusion in people undergoing coronary surgery: A systematic review and meta-analysis." Avicenna journal of medicine vol. 10,4 (2020): 198-207. doi: https://doi.org/10.4103/ajm.ajm_17_20
Alahdab F, Zuhri Yafi R, Chaar A, Alrstom A, Alzuabi M, Alhalabi O, Hasan S, Mallak M, Jazayerli ML, Haydour Q, Alkhouli M, Alfarkh W, Murad MH. Aspirin dosage for the prevention of graft occlusion in people undergoing coronary surgery: A systematic review and meta-analysis. Avicenna J Med. 2020 Oct 13;10(4):198-207. doi: 10.4103/ajm.ajm_17_20. eCollection 2020. PMID: 33437691; PMCID: PMC7791283.
Copy Download .nbib Format: NLM
Where should preappraised evidence summaries and guidelines place in a pyramid?.

Evidence-based medicine

Alahdab F, Alsawas M, Murad MH.
PMID: 27777249
Evid Based Med. 2016 Dec;21(6):240. doi: 10.1136/ebmed-2016-110571. Epub 2016 Oct 24.

No abstract available.

Cite
Alahdab F, Alsawas M, Murad MH. Where should preappraised evidence summaries and guidelines place in a pyramid?. Evid Based Med. 2016;21(6):240doi: 10.1136/ebmed-2016-110571.
Alahdab, F., Alsawas, M., & Murad, M. H. (2016). Where should preappraised evidence summaries and guidelines place in a pyramid?. Evidence-based medicine, 21(6), 240. https://doi.org/10.1136/ebmed-2016-110571
Alahdab, Fares, et al. "Where should preappraised evidence summaries and guidelines place in a pyramid?." Evidence-based medicine vol. 21,6 (2016): 240. doi: https://doi.org/10.1136/ebmed-2016-110571
Alahdab F, Alsawas M, Murad MH. Where should preappraised evidence summaries and guidelines place in a pyramid?. Evid Based Med. 2016 Dec;21(6):240. doi: 10.1136/ebmed-2016-110571. Epub 2016 Oct 24. PMID: 27777249.
Copy Download .nbib Format: NLM
Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study.

JAMA neurology

, Feigin VL, Vos T, Alahdab F, Amit AML, Bärnighausen TW, Beghi E, Beheshti M, Chavan PP, Criqui MH, Desai R, Dhamminda Dharmaratne S, Dorsey ER, Wilder Eagan A, Elgendy IY, Filip I, Giampaoli S, Giussani G, Hafezi-Nejad N, Hole MK, Ikeda T, Owens Johnson C, Kalani R, Khatab K, Khubchandani J, Kim D, Koroshetz WJ, Krishnamoorthy V, Krishnamurthi RV, Liu X, Lo WD, Logroscino G, Mensah GA, Miller TR, Mohammed S, Mokdad AH, Moradi-Lakeh M, Morrison SD, Shivamurthy VKN, Naghavi M, Nichols E, Norrving B, Odell CM, Pupillo E, Radfar A, Roth GA, Shafieesabet A, Sheikh A, Sheikhbahaei S, Shin JI, Singh JA, Steiner TJ, Stovner LJ, Wallin MT, Weiss J, Wu C, Zunt JR, Adelson JD, Murray CJL.
PMID: 33136137
JAMA Neurol. 2021 Feb 01;78(2):165-176. doi: 10.1001/jamaneurol.2020.4152.

IMPORTANCE: Accurate and up-to-date estimates on incidence, prevalence, mortality, and disability-adjusted life-years (burden) of neurological disorders are the backbone of evidence-based health care planning and resource allocation for these disorders. It appears that no such estimates have been reported...

Cite
, Feigin VL, Vos T, et al. Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study. JAMA Neurol. 2021;78(2):165-176doi: 10.1001/jamaneurol.2020.4152.
, Feigin, V. L., Vos, T., Alahdab, F., Amit, A. M. L., Bärnighausen, T. W., Beghi, E., Beheshti, M., Chavan, P. P., Criqui, M. H., Desai, R., Dhamminda Dharmaratne, S., Dorsey, E. R., Wilder Eagan, A., Elgendy, I. Y., Filip, I., Giampaoli, S., Giussani, G., Hafezi-Nejad, N., Hole, M. K., Ikeda, T., Owens Johnson, C., Kalani, R., Khatab, K., Khubchandani, J., Kim, D., Koroshetz, W. J., Krishnamoorthy, V., Krishnamurthi, R. V., Liu, X., Lo, W. D., Logroscino, G., Mensah, G. A., Miller, T. R., Mohammed, S., Mokdad, A. H., Moradi-Lakeh, M., Morrison, S. D., Shivamurthy, V. K. N., Naghavi, M., Nichols, E., Norrving, B., Odell, C. M., Pupillo, E., Radfar, A., Roth, G. A., Shafieesabet, A., Sheikh, A., Sheikhbahaei, S., Shin, J. I., Singh, J. A., Steiner, T. J., Stovner, L. J., Wallin, M. T., Weiss, J., Wu, C., Zunt, J. R., Adelson, J. D., & Murray, C. J. L. (2021). Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study. JAMA neurology, 78(2), 165-176. https://doi.org/10.1001/jamaneurol.2020.4152
, et al. "Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study." JAMA neurology vol. 78,2 (2021): 165-176. doi: https://doi.org/10.1001/jamaneurol.2020.4152
, Feigin VL, Vos T, Alahdab F, Amit AML, Bärnighausen TW, Beghi E, Beheshti M, Chavan PP, Criqui MH, Desai R, Dhamminda Dharmaratne S, Dorsey ER, Wilder Eagan A, Elgendy IY, Filip I, Giampaoli S, Giussani G, Hafezi-Nejad N, Hole MK, Ikeda T, Owens Johnson C, Kalani R, Khatab K, Khubchandani J, Kim D, Koroshetz WJ, Krishnamoorthy V, Krishnamurthi RV, Liu X, Lo WD, Logroscino G, Mensah GA, Miller TR, Mohammed S, Mokdad AH, Moradi-Lakeh M, Morrison SD, Shivamurthy VKN, Naghavi M, Nichols E, Norrving B, Odell CM, Pupillo E, Radfar A, Roth GA, Shafieesabet A, Sheikh A, Sheikhbahaei S, Shin JI, Singh JA, Steiner TJ, Stovner LJ, Wallin MT, Weiss J, Wu C, Zunt JR, Adelson JD, Murray CJL. Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study. JAMA Neurol. 2021 Feb 01;78(2):165-176. doi: 10.1001/jamaneurol.2020.4152. PMID: 33136137; PMCID: PMC7607495.
Copy Download .nbib Format: NLM
High-altitude hypoxia exacerbates dextran sulfate sodium (DSS)-induced colitis by upregulating Th1 and Th17 lymphocytes.

Bioengineered

Gamah M, Alahdal M, Zhang Y, Zhou Y, Ji Q, Yuan Z, Han Y, Shen X, Ren Y, Zhang W.
PMID: 34666625
Bioengineered. 2021 Dec;12(1):7985-7994. doi: 10.1080/21655979.2021.1975017.

High altitude hypoxia (HAH) involves the pathogenesis of ulcerative colitis (UC) and gastrointestinal erosions. However, the mechanism of effects of HAH in colitis remains controversial. This study reports the immunomodulation mediated by HAH to enhancing the severity of UC...

Cite
Gamah M, Alahdal M, Zhang Y, et al. High-altitude hypoxia exacerbates dextran sulfate sodium (DSS)-induced colitis by upregulating Th1 and Th17 lymphocytes. Bioengineered. 2021;12(1):7985-7994doi: 10.1080/21655979.2021.1975017.
Gamah, M., Alahdal, M., Zhang, Y., Zhou, Y., Ji, Q., Yuan, Z., Han, Y., Shen, X., Ren, Y., & Zhang, W. (2021). High-altitude hypoxia exacerbates dextran sulfate sodium (DSS)-induced colitis by upregulating Th1 and Th17 lymphocytes. Bioengineered, 12(1), 7985-7994. https://doi.org/10.1080/21655979.2021.1975017
Gamah, Mohammed, et al. "High-altitude hypoxia exacerbates dextran sulfate sodium (DSS)-induced colitis by upregulating Th1 and Th17 lymphocytes." Bioengineered vol. 12,1 (2021): 7985-7994. doi: https://doi.org/10.1080/21655979.2021.1975017
Gamah M, Alahdal M, Zhang Y, Zhou Y, Ji Q, Yuan Z, Han Y, Shen X, Ren Y, Zhang W. High-altitude hypoxia exacerbates dextran sulfate sodium (DSS)-induced colitis by upregulating Th1 and Th17 lymphocytes. Bioengineered. 2021 Dec;12(1):7985-7994. doi: 10.1080/21655979.2021.1975017. PMID: 34666625.
Copy Download .nbib Format: NLM
Medication-Related Burden and Medication Adherence Among Geriatric Patients in Kuwait: A Cross-Sectional Study.

Frontiers in pharmacology

Awad A, Alhadab A, Albassam A.
PMID: 32973523
Front Pharmacol. 2020 Aug 21;11:1296. doi: 10.3389/fphar.2020.01296. eCollection 2020.

The evaluation of medicines burden from the patients' perspectives is a crucial endeavor to identify any barriers that may hinder achieving optimal health outcomes. Therefore, this study was designed, firstly to identify the prevalence of medication-related burden among geriatrics...

Cite
Awad A, Alhadab A, Albassam A. Medication-Related Burden and Medication Adherence Among Geriatric Patients in Kuwait: A Cross-Sectional Study. Front Pharmacol. 2020;11:1296doi: 10.3389/fphar.2020.01296.
Awad, A., Alhadab, A., & Albassam, A. (2020). Medication-Related Burden and Medication Adherence Among Geriatric Patients in Kuwait: A Cross-Sectional Study. Frontiers in pharmacology, 111296. https://doi.org/10.3389/fphar.2020.01296
Awad, Abdelmoneim, et al. "Medication-Related Burden and Medication Adherence Among Geriatric Patients in Kuwait: A Cross-Sectional Study." Frontiers in pharmacology vol. 11 (2020): 1296. doi: https://doi.org/10.3389/fphar.2020.01296
Awad A, Alhadab A, Albassam A. Medication-Related Burden and Medication Adherence Among Geriatric Patients in Kuwait: A Cross-Sectional Study. Front Pharmacol. 2020 Aug 21;11:1296. doi: 10.3389/fphar.2020.01296. eCollection 2020. PMID: 32973523; PMCID: PMC7472566.
Copy Download .nbib Format: NLM
Analysis of FDA Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations.

Clinical pharmacology and therapeutics

Yang DZ, Alhadab A, Parivar K, Wang DD, Elmeliegy M.
PMID: 34870845
Clin Pharmacol Ther. 2021 Dec 06; doi: 10.1002/cpt.2505. Epub 2021 Dec 06.

Cancer patients with advanced hepatic impairment (HI) (ie, moderate and severe impairment) are often excluded from first-in-patient, phase II, and III studies. Thus, dose recommendations for this subgroup of patients are often derived using a combination of dedicated phase...

Cite
Yang DZ, Alhadab A, Parivar K, et al. Analysis of FDA Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations. Clin Pharmacol Ther. 2021;doi: 10.1002/cpt.2505.
Yang, D. Z., Alhadab, A., Parivar, K., Wang, D. D., & Elmeliegy, M. (2021). Analysis of FDA Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations. Clinical pharmacology and therapeutics, . https://doi.org/10.1002/cpt.2505
Yang, Derek Z, et al. "Analysis of FDA Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations." Clinical pharmacology and therapeutics vol. (2021). doi: https://doi.org/10.1002/cpt.2505
Yang DZ, Alhadab A, Parivar K, Wang DD, Elmeliegy M. Analysis of FDA Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations. Clin Pharmacol Ther. 2021 Dec 06; doi: 10.1002/cpt.2505. Epub 2021 Dec 06. PMID: 34870845.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 59 entries